In order to improve the detection capabilities of anabolic androgenic steroids (AAS) in sports, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for the simultaneous detection of AAS phase I and phase II intact urinary metabolites (glucuronides and sulfates) was developed.
Introduction
Anabolic androgenic steroids (AAS) are prohibited in sports due to their performance enhancing properties.
They are the most frequently reported group of prohibited substances detected in doping controls, reflecting the wide use of these drugs among athletes [1] . There is a need to continuously improve the detection capabilities of the AAS misuse. The best markers of the administration are the metabolites detected for long time in urine, the so-called long-term metabolites.
Most AAS are extensively metabolized and they are mainly excreted in urine as phase II metabolites [2-4].
However, for many AAS most of the metabolic profile remains unknown [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Studies on phase II steroid metabolism have been traditionally performed using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS), after hydrolysis to release the phase I metabolites [2-4,9-11]. Since most studies used preparations with β-glucuronidase enzymes or preparations with β-glucuronidase and arylsulfatase activities, that show low efficacy to cleave most of the steroid sulfates [16] , only glucuronoconjugated metabolites hydrolysable in these conditions and free excreted metabolites have been systematically studied.
In recent years, new phase II metabolites have been identified for some AAS using their direct analysis by LC-MS and some of them have shown to be useful as long-term metabolites. Boldenone, boldione, methyltestosterone and metandienone metabolites conjugated with sulfate have been recently identified [5] [6] [7] [8] 12 ]. Glucuronoconjugated metabolites poorly or not hydrolysable using β-glucuronidases have been described for testosterone and stanozolol [13, 14] . These results demonstrate the need to re-evaluate AAS metabolism to study new phase II metabolites not systematically studied up to now, to look for new long-term metabolites, and to include these new metabolites in the routine screening procedures.
Current screening methods for AAS are based on the hydrolysis of the urine using β-glucuronidase enzymes, and analysis using both GC-MS and LC-MS technologies [17, 18] . Therefore, only unconjugated metabolites and hydrolyzable glucuronic acid conjugates are detectable. Moreover, it is known that the time required to complete the hydrolysis varies between the different steroid glucuronides [19, 20] and the hydrolysis may also be incomplete in particular urine matrices due to enzyme inhibition [21] . As a consequence, some metabolites may be underestimated due to incomplete hydrolysis. Furthermore, the current procedure is time consuming and requires the combination of two technologies to ensure detection of all compounds: the need for derivatization before GC-MS analysis limits the analysis of some phase I metabolites that do not form suitable derivatives [18] ; and, other phase I metabolites cannot be detected using LC-MS due to the lack of ionizable groups [22] .
Steroid glucuronides and sulfates are readily ionized using electrospray ionization [12, 13, 18, 23, 24] , and methods describing the direct analyses of AAS conjugates by LC-MS have been published although the lack of reference materials has been often a drawback [23, 25, 26] . Recently, a screening method using liquid chromatography-high resolution mass spectrometry (LC-HRMS) has been described for exogenous AAS [27] .
The method was mainly based on the detection of AAS metabolites monitored in the currently used screening strategies and , for some of the compounds, the required limits of detection were not achieved [28] .
The aim of the present study was to develop a comprehensive screening method consisting of the analysis of unaltered phase I and phase II metabolites of exogenous AAS by LC-MS/MS. Recently described long-term metabolites as well as the metabolites monitored in the currently used screening procedure were incorporated.
The suitability of the method to detect all type of metabolites (unconjugated, glucuronides and sulfates) was evaluated by using excretion study samples of different AAS.
Materials and methods

Chemical and reagents
17β-nandrolone 17-sulfate (17-NAN-S) and oxandrolone (OXA) were obtained from Steraloids (Newport, USA). 17α-methyl-5α-androstan-3α,17β-diol (METm1), 17α-methyl-5β-androstan-3α,17β-diol (METm2), 5α-androstane-3α, 17β-diol 17-glucuronide, 5α-androstane-3α, 17β-diol 3-glucuronide, 5β-androstane-3α, 17β-diol 17-glucuronide, 5β-androstane-3α, 17β-diol 3-glucuronide, 5α-androstane-3β, 17β-diol 3-glucuronide, 5β-androst-1-ene-17β-ol-3-one 17-glucuronide (BOLDm-G), 5β-androstan-7β,17α-dimethyl-3α,17β-diol 3-glucuronide (CALm-G), bolasterone 3-glucuronide (BOLm-G), 17β-boldenone 17-glucuronide (BOLD-G), 17β-boldenone 17-sulfate (BOLD-S), epimetandienone (MEDm2), epioxandrolone (OXAm), 9-fluoro-18-nor-17,17-dimethyl-4,13-diene-11-ol-3-one (FLUm3), 3'-hydroxystanozolol 3'-glucuronide (3STAN-G), 6β-hydroxy-metandienone (MEDm1), 6β-hydroxy-4-chloro-metandienone (4CMDm), 1-methylen-5α-androstan-3α-ol-17-one 3-glucuronide (MTNm-G), 1α-methyl-5α-androstan-3α-ol-17-one 3-glucuronide (MESm1-G), 1α-methyl-5α-androstan-3α-,17β-diol 3-glucuronide (MESm2-G), 2α-methyl-5α-androstan-3α-ol-17-one 3-glucuronide (DROm-G), 17α-nandrolone 17-sulfate (17-NAN-S), 17β-nandrolone 17-glucuronide (17-NAN-G), 19-norandrosterone 3-glucuronide (NA-G), 19-norandrosterone 3-sulfate (NA-S), 19-noretiocholanolone 3-glucuronide (NE-G) and 19-noretiocholanolone 3-sulfate (NE-S) were supplied by NMI Australian Government (Pymble, Australia). Methyltestosterone (MET), from Toronto Research Chemicals (Toronto, Canada), and, androsterone-d4 3-glucuronide (d4-And-G), nandrolone-d3 17-sulfate (d3-NAN-S) and testosterone-d3 17-glucuronide (d3-T-G), from NMI Australian Government (Pymble, Australia), were used as internal standards (IS).
Acetonitrile (ACN) (LC gradient grade) and methanol (MeOH) (LC grade), formic acid (LC/MS grade) and ammonium formate were obtained from Merck (Darmstadt, Germany). Acetobromo-α-D-glucuronic acid methyl ester (α-D-Glucopyranuronic acid, 1-bromo-1-deoxy-, methyl ester, 2,3,4-triacetate), toluene, Ag 2 CO 3 and LiOH were purchased from Sigma-Aldrich Química S.A. (Madrid, Spain). Milli Q quality water was used (Millipore Ibérica, Barcelona, Spain). Sep-Pak Vac RC C18 (500 mg) cartridges were purchased from Waters (Milford, Massachusetts, USA).
Sample preparation
After the addition of 20 µL of the Internal Standards (IS) solution (MET, d3-NAN-S and d3-T-G at 1 µg/mL, and d4-And-G at 5 µg/mL), urine samples (2 mL) were vortex-mixed and passed through a C18 cartridge previously conditioned with MeOH (2 mL) and water (2 mL). The column was then washed with water (2 mL), and the analytes were eluted with MeOH (2 mL). The samples were evaporated to dryness under nitrogen stream in a bath at 40 ºC. The extract was re-dissolved into 200 L of a solution of ACN:water (10:90, v/v). A volume of 10L was injected into the LC-MS/MS.
LC-MS/MS instrumental conditions
Detection was carried out using a triple quadrupole (XEVO TQMS) mass spectrometer equipped with an orthogonal Z-spray-electrospray ionization source (ESI) (all from Waters -Corporation, Milford, MA, USA).
Drying gas as well as nebulizing gas was nitrogen. The desolvation gas flow was set to 1200 L/h, and the cone gas flow was 50 L/h. The nitrogen desolvation temperature was 450 ºC, and the source temperature was 120 ºC.
Chromatographic separations were carried out on an Acquity UPLC ® system (Waters Corporation) using an Acquity UPLC ® BEH C18 column (2.1 mm x 100 mm i.d., 1.7 µm particle size). The column temperature was set to 45 °C and the flow rate was 0.3 mL/min.
In order to optimize the mobile phase composition, four different mobile phases (MP-1 to MP-4) were Mass spectrometric conditions were optimized by infusing methanolic solutions of the compounds. For steroid metabolites not available as standards, optimization was performed using extracts from urines obtained after administration of the AAS. Capìllary voltage and cone voltage were optimized to obtain maximum signal for the parent ions. Collision energies were studied in order to obtain the maximum response for the product ions.
For the final screening method, a selected reaction monitoring (SRM) method using retention windows was set up. The two most specific transitions for each compound were selected by evaluation of the signal intensity and the urine background in 10 different blank urines spiked with the metabolites at different concentrations (0.5, 1, 2, 5, 10 and 50 ng/ml). The mass spectrometric conditions of the SRM method are described in Table 1 . Switching polarity was used throughout the runs.
Method validation
The method was validated for qualitative purposes according to the World Antidoping Agency (WADA) requirements using a previously described protocol [29] .
The limit of detection (LOD) was evaluated by using decreasing concentrations of the analytes in 10 different urines. The LOD was defined as the lowest concentration at which an analyte was detected in all 10 urine samples with a signal-to-noise ratio of at least 3.
Within-day precision was assessed by analysis of 6 replicates of a urine sample on the same day spiked at two concentrations levels: low (LCL) and upper (UCL). The LCL was the LOD and the UCL was between 2.5 and 10 fold the LOD. Results were expressed as % relative standard deviation (%RSD) of the area ratios between the analyte and the IS. MET was used as IS for the phase I metabolites, d4-And-G for glucuronides ionizing as Lack of carryover was demonstrated by injecting blank urine extracts immediately after samples spiked at the UCL with all analytes. Carryover was considered negligible if analytes were not detected in the blank urines.
Matrix effect (ME) was assessed by a post column infusion strategy previously described [30, 31] . A constant flow (2 µL/min) of a solution of each analyte (10 µg/mL) was added after the chromatographic column while an injection of mobile phase solvent and injections of different extracted blank urines (n=4) were carried out.
Signal intensities of the ion transition of each analyte for the mobile phase solvent were given 100% (no ME). The synthesis of the glucuronides was based on a previously described method [32, 33] . Briefly, in 0.5 mL of toluene, 100 µg (0.36 µmol, 1 equivalent) of either 17α-methyl-5α-androstan-3α,17β-diol or 17α-methyl-5β-androstan-3α,17β-diol were added followed by 142 µg (0.36 µmol, 1 equivalent) of acetobromo-α-Dglucuronic acid methyl ester and 500 µg of Ag 2 CO 3 . The reaction mixture was left under vigorous stirring for 24 h at 75 ºC. Then, the mixture was cooled to room temperature, filtered and evaporated to dryness under vacuum. The solid residue was dissolved in 0.5 mL of MeOH followed by the addition of 0.5 mL of aqueous LiOH 1 M. After 28 h of stirring at room temperature, the solvents were removed under vacuum.
Excretion study samples
Urines samples collected before and after administration of AAS to healthy male volunteers were used for this study. In addition, for the validation study, drug-free urine samples were collected from ten healthy volunteers and kept frozen at -20ºC. 
Results and discussion
Mass spectrometric behavior of steroid phase I and phase II metabolites.
To study the mass spectrometric behavior, AAS metabolites were divided in four groups according to their structural features: I, unconjugated steroid metabolites; II, glucuronides with  n -3 CO function or pirazole ring; III, glucuronides without  n -3 CO function; and IV, sulfate metabolites (Table 2 and Fig S-3 supp. mat).
Results obtained regarding ionization and collision induced dissociation (CID) behaviors were in agreement with those previously described [18] and are summarized in sulfates was also evaluated, negative ion mode was used in this study for all sulfates as it always yielded most intense signals.
The CID gave common ions or losses depending on the analytes chemical features ( 
Mobile phase composition.
The ionization efficiency of the analytes depends on the mobile phase composition, and it was optimized.
Hence, four different mobile phases were tested (MP-1 to MP-4, see experimental section) using combinations of MeOH and ACN, and modifiers such as ammonium formate. For MP-3, the 5% of water in ACN (solvent B) facilitated the solubility of ammonium formate.
The mass spectrometric behavior of four analytes representing the selected groups of compounds (I, MEDm2;
II, BOLDm-G; III, MTNm-G; IV, BOLD-S) was investigated. Urine samples, spiked with these analytes at 100 ng/mL and extracted using the procedure described in experimental section, were analyzed using the different mobile phases. Signal intensities, signal-to-noise ratios and chromatographic resolutions were , less interferent peaks and also better chromatographic resolution regarding pairs of isomers. Therefore, conditions MP-3 were selected to be used in the screening procedure.
Selection of the target ion transitions.
The ion transitions to monitor each steroid metabolite were selected based on the signal intensity and the selectivity. These parameters were evaluated for different ion transitions of each analyte by using ten different urine samples spiked with the analytes at different concentrations. The selection was compound dependent, and ion transitions included in the final SRM method are listed in Table 1 . For sulfate conjugates, the ion transitions that yielded the highest signal were those to the product ion m/z 97 and, for most sulfate metabolites, only these transitions were monitored (Table 1) , resulting in high sensitivity and specificity for these compounds. However, for other sulfates with molecular masses closer to endogenous compounds such as BOLD-S, the ion transition [M-H] -to m/z 97 showed low specificity and ion transitions resulting from characteristic fragmentations (m/z 365→350, m/z 365→177) [12] had to be used to obtain the highest selectivity and adequate LOD (Figure 1 (a) ). The poor LOD described for BOLD-S in a recent study using LC-HRMS was due to the presence of endogenous interferences when using either
For the majority of glucuronides, the ion transitions were related to the glucuronide moiety and the best signal (Table 1) .
Method validation
The method was validated for qualitative purposes using the AAS metabolites available as reference standards. Results of LOD, extraction recovery, repeatability at two concentrations levels and ME are listed in Table 3 .
The method showed to be selective and specific, as no matrix interferences were detected at the retention The extraction recoveries were better than 77% and, therefore, the sample pre-treatment procedure was appropriate to recover free as well as conjugated metabolites. As for the current methods to detect AASs, a substantial reduction of time in sample preparation procedure was achieved due to the elimination of the hydrolysis and derivatisation procedures.
Good intra-assay precision was obtained, with RSD values within the normally accepted ranges, lower than 15% for the UCL studied and lower than 25% for the LCL.
Detection of the analytes can be affected by ion suppression or enhancement due the impact of coeluting substances of the urine matrix. Results showed moderate enhancement (from 104 to 147 %) of the analytes ions intensities except for FLUm3 that showed small suppression (Table 3) . RSD values were lower than 10%, indicating similar behavior between the different urine matrices.
A detail of the results obtained in the evaluation of the LOD is shown in Table S -6 (supp. mat.) and results are summarized in Table 3 . The LODs obtained ranged from 0.25 to 4 ng/mL for free metabolites, from 0.25 to 0.5 ng/mL for sulfate conjugates and from 0.5 to more than 20 ng/mL for glucuronide conjugates. The LOD required by WADA for AAS metabolites is 2.5 ng/mL of the phase I metabolite except for dehydrochlormethyltestosterone, methandienone, methyltestosterone and stanozolol metabolites for which the required LOD is 1 ng/mL [28] . Taking into consideration that a concentration of 2.5 ng/mL of the phase I metabolite is equivalent to approximately 4 and 3 ng/mL of the glucuronides and sulfates, respectively, the LODs obtained for most of the compounds are in agreement with WADA requirements.
Five glucuronides (MESm1-G, 17β-NAN-G, BOLDm-G, CALmG and BOLmG) and two unconjugated (MEDm1 and 4CMEDm) metabolites showed LODs greater than those required (Table 3) . For MESm1-G, 17β-NAN-G and BOLDm-G (metabolites of mesterolone, nandrolone and boldenone respectively), other metabolites of these AAS are included in the procedure with good LOD (MESm2-G for mesterolone; NE-G, NA-G, NE-S and NA-S for nandrolone; and BOLD-G, BOLD-S and eBOLD-S for boldenone). Therefore, the detection capabilities of these AAS are not compromised. Similarly, the relatively high LOD of MEDm1 does not compromise the detection of metandienone misuse because other metabolites, including a recently described long-term metabolite, MEDm-S, are also monitored [7] (Figure S-2 supp. mat.). 4CMEDm is a metabolite present in urine during the first days after administration of dehydrochlormethyltestosterone, and the improvement in the detection capabilities for that AAS has to be achieved by monitoring the recently described long-term metabolites excreted as glucuronides [9] . Finally, the poor detection of CALm-G and BOLm-G suggests the need to perform metabolic studies of calusterone and bolasterone to look for alternative metabolites to be included in the method in order to improve the detection of these AAS using the proposed procedure.
Previous works involving the detection of five intact AAS glucuronide metabolites [35] showed LODs in the range 5-10 ng/mL. A recently published method using urine dilution and LC-HRMS analysis [27] showed higher LODs for all unconjugated and sulfate metabolites except for OXAm for which the same LOD was obtained. Regarding glucuronide metabolites, LODs were from 2 to 26 fold higher with the exception of CALm-G and BOLm-G. These results indicate the importance of using a sample preparation procedure and more selective ion transitions, as in our procedure, to achieve the required sensitivity.
Results of one of the blank urine samples spiked with the 23 studied compounds at their LODs are shown in 
Inclusion of recently described long-term metabolites of some AAS
New long-term phase II metabolites have been recently described for some AAS (e.g., boldenone, metandienone, methyltestosterone and stanozolol), for which standards are not commercially available Due to the importance of METm1-G and METm2-G in the currently used screening procedures and in WADA requirements [28] , these metabolites were qualitatively synthesized and the analysis revealed the occurrence of one peak for METm1-G and two peaks for METm2-G corresponding to the 3-/17-glucuronide isomers. The identification of these isomers (Table 1) was based on the comparison of chromatographic and mass spectrometric data with data obtained for androstanediol metabolites which have a similar structure and the four possible metabolites commercially available (data not shown).
Excretion studies of methyltestosterone and stanozolol.
The method was tested using samples collected after administration of the AAS to volunteers. As an example of the usefulness and capabilities of the developed method for screening purposes, results of the analysis of methyltestosterone and stanozolol excretion urine samples are presented. reported detection times for these metabolites using other analytical approaches [6] . As mentioned, so far these sulfate metabolites are not monitored in the current screening methods used in most laboratories.
Detection of the unconjugated metabolite METm5 is around one week, in accordance with previously reported data using LC-MS/MS analysis [6] . Furthermore, detection of unaltered glucuronide metabolites METm1-G and METm2-3-G was up to 1 and 4 days, respectively. Using GC-MS/MS analysis after hydrolysis and derivatization, detection times of 4 and 6 days were described for METm1-G and METm2-G, respectively [6, 36] . The developed methodology could distinguish the two different METm2-G isomers (METm2-3-G and
METm2-17-G) which are observed in only one peak (corresponding to the phase I metabolite) using the GC-MS/MS procedure. This could partially explain the differences in detection times observed for METm2-G.
However, the main reasons for these differences are the high sensitivity of GC-MS/MS analysis for the phase I metabolites, METm1 and METm2, and a low sensitivity for the glucuronides METm1-G and METm2-G in LC-MS/MS, that need to be ionized through the formation of the adduct ion [M+NH 4 ] + due to the lack of ionizable groups in the steroid structure.
Results show that although the detection times obtained for some metabolites are lower (and probably the LOD higher) than using conventional screening methods, the capabilities of the detection of methyltestosterone misuse have been improved using the proposed procedure from 6 to 22 days after administration, through the monitoring of new long-term metabolites. It is worth mentioning that the proposed procedure allows for the detection of different types of metabolites (unconjugated metabolites and conjugates with glucuronic acid or sulfate) that need three different methods using the conventional approaches [6] .
Results obtained after analysis of stanozolol samples are shown in to obtain cleaner extracts for confirmation purposes as previously described [37] .
Conclusions
A LC-MS/MS screening method for the simultaneous detection of phase I and phase II intact urinary metabolites of exogenous AAS was developed and fully validated for the first time. The validation criteria were met and the method was considered compliant with WADA requirements for most of the analytes.
Moreover, it represents a much simple approach with a less time-consuming sample preparation compared to what conventional LC-MS and GC-MS methods require. Automatization of the procedure with an on-line solid phase extraction system could be easily implemented in the future. In addition, the method improves the detection capabilities through the monitoring of important long term metabolites not detectable using the current screening strategy and, also, it could incorporate new long-term phase II metabolites described in the future irrespective of their nature. Endogenous AAS metabolites could be, as well, included in the method. In order to demonstrate the suitability of the strategy methyltestosterone and stanozolol excretion study urines were analysed reaching detection times of 22 and 21 days, respectively. The method can readily be incorporated to WADA accredited laboratories as it offers a direct and sensitive approach to the analysis of exogenous steroids. 4STAN-G, 16STAN-G, 3STAN-G, STAN-N-G, STAN-O-G and eSTAN-N Table 1 
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